[go: up one dir, main page]

UY35545A - Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coag ulación - Google Patents

Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coag ulación

Info

Publication number
UY35545A
UY35545A UY0001035545A UY35545A UY35545A UY 35545 A UY35545 A UY 35545A UY 0001035545 A UY0001035545 A UY 0001035545A UY 35545 A UY35545 A UY 35545A UY 35545 A UY35545 A UY 35545A
Authority
UY
Uruguay
Prior art keywords
procedures
coag
ulation
compositions
factory
Prior art date
Application number
UY0001035545A
Other languages
English (en)
Inventor
Aswad Fred
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of UY35545A publication Critical patent/UY35545A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente documento se proporcionan conjugados para inducir tolerancia de la proteína factor de coagulación, en el que el conjugado comprende una proteína factor de coagulación o un fragmento antigénico o variante del mismo y un ligando Siglec. También se proporcionan composiciones farmaceúticas, procedimientos y kits que comprenden los conjugados.
UY0001035545A 2013-04-28 2014-04-28 Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coag ulación UY35545A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361816790P 2013-04-28 2013-04-28

Publications (1)

Publication Number Publication Date
UY35545A true UY35545A (es) 2014-11-28

Family

ID=50846907

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035545A UY35545A (es) 2013-04-28 2014-04-28 Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coag ulación

Country Status (11)

Country Link
US (1) US20160279252A1 (es)
EP (1) EP2991684B1 (es)
JP (1) JP2016519120A (es)
CN (1) CN105451774A (es)
AR (1) AR096123A1 (es)
CA (1) CA2910277A1 (es)
ES (1) ES2691041T3 (es)
HK (1) HK1217167A1 (es)
TW (1) TW201519900A (es)
UY (1) UY35545A (es)
WO (1) WO2014179184A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014176125A1 (en) * 2013-04-22 2014-10-30 The Scripps Research Institute Methods and compositions for treating bleeding disorders
KR20190012189A (ko) * 2016-05-20 2019-02-08 옥타파마 아게 약동학이 개선된 글리코실화 vwf 융합 단백질
CN108926719B (zh) * 2017-05-25 2020-09-01 北京格瑞特森生物医药科技有限公司 用c(RGD-ACP-K)修饰的长循环脂质体
WO2018225873A1 (ja) * 2017-06-09 2018-12-13 協和発酵キリン株式会社 核酸含有ナノ粒子
EP3839059A1 (en) * 2019-12-16 2021-06-23 CGT Enterprises, LLC Devices and methods for determining coagulation factor activities
US20240216490A1 (en) * 2022-07-13 2024-07-04 Osprey Biopharmaceuticals, Inc. Autoantigens Engineered to Suppress Autoimmune Response
CN116036244B (zh) * 2023-02-24 2023-09-19 北京基科晟斯医药科技有限公司 培重组人凝血因子VIII-Fc融合蛋白用于治疗含抑制物的血友病A的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2549413A1 (en) * 2003-12-03 2005-06-23 Neose Technologies, Inc. Glycopegylated factor ix
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
KR101237884B1 (ko) * 2003-12-03 2013-02-27 바이오제너릭스 에이지 글리코 peg화 과립구 콜로니 자극인자
US7632921B2 (en) * 2004-11-12 2009-12-15 Bayer Healthcare Llc Site-directed modification of FVIII
WO2007047654A2 (en) * 2005-10-17 2007-04-26 Health Research, Inc. Specific acceptors for tranferases to saccharides and method for obtaining and using same
AU2010278721A1 (en) * 2009-07-31 2012-02-16 Bayer Healthcare Llc Modified factor IX polypeptides and uses thereof

Also Published As

Publication number Publication date
CA2910277A1 (en) 2014-11-06
JP2016519120A (ja) 2016-06-30
EP2991684A1 (en) 2016-03-09
EP2991684B1 (en) 2018-07-11
US20160279252A1 (en) 2016-09-29
AR096123A1 (es) 2015-12-09
WO2014179184A1 (en) 2014-11-06
TW201519900A (zh) 2015-06-01
WO2014179184A8 (en) 2015-10-29
CN105451774A (zh) 2016-03-30
HK1217167A1 (zh) 2016-12-30
ES2691041T3 (es) 2018-11-23

Similar Documents

Publication Publication Date Title
FR21C1030I2 (fr) Conjugué anticorps anti-her2-médicament
UY35545A (es) Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coag ulación
MX2015015239A (es) Composiciones y metodos.
CY1124521T1 (el) Σκευασματα αντισωματος anti-cd19
MX385749B (es) Composiciones que comprenden una caseína y métodos para producir las mismas.
BR112016025291A2 (pt) conjugados de anticorpo anti-ptk7-fármaco
EP3549589A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING MITOCHONDRIA
BR112019004785A2 (pt) variantes de alfa-glicosidase ácida e usos das mesmas
MX2017007585A (es) Anticuerpos anti-c10orf54 y usos de los mismos.
MX391989B (es) Conjugados de amatoxina y anticuerpos.
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
UY36186A (es) Ácidos grasos novedosos y su uso en la conjugación con biomoléculas
PE20150646A1 (es) Metodos de tratamiento de una tauopatia
BR112015009924A2 (pt) formulações de proteína imunoglobulina de domínio variável duplo estáveis
UY4235Q (es) Configuración aplicada en zapato
BR112019004783A2 (pt) variantes de alfa-glicosidase ácida e usos das mesmas
CR20150626A (es) Anticuerpos frente a ácidos teicoicos de pared y conjugados
EP3355931C0 (en) PROTEIN CONJUGATES
MX2023006416A (es) Anticuerpos, usos y metodos.
CO2017007316A2 (es) Formulación farmacéutica
SI3435980T1 (sl) Fiziološko uravnotežene injektabilne formulacije fosnetupitanta
BR112016019389A8 (pt) Vacina, e, peptídeo
IL279855A (en) Improvements in immunogenic conjugates
DK3666787T3 (da) Antistoflægemiddelkonjugater som inkluderer hemiasterlinderivat
EP3609527C0 (en) PROTEIN CONJUGATES

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211206